Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
DaShenLin Pharmaceutical Group Co's 3-Year RORE % for the quarter that ended in Mar. 2026 was 27.55%.
SHSE:603233's 3-Year RORE % is ranked better than 74.71% of 597
companies
in the Healthcare Providers & Services industry
Industry Median: 1.57
vs SHSE:603233: 27.55
DaShenLin Pharmaceutical Group Co (SHSE:603233) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
DaShenLin Pharmaceutical Group Co 3-Year RORE % Related Terms
DaShenLin Pharmaceutical Group Co 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DaShenLin Pharmaceutical Group Co 3-Year RORE % Chart
DaShenLin Pharmaceutical Group Co 3-Year RORE % Competitor Comparison
For the Pharmaceutical Retailers subindustry, DaShenLin Pharmaceutical Group Co's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DaShenLin Pharmaceutical Group Co 3-Year RORE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DaShenLin Pharmaceutical Group Co's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where DaShenLin Pharmaceutical Group Co's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
DaShenLin Pharmaceutical Group Co (SHSE:603233) has a 3-Year RORE % of 27.55 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on DaShenLin Pharmaceutical Group Co and its competitors. According to the industry distribution chart, DaShenLin Pharmaceutical Group Co ranks #151 out of 597 companies in the Healthcare Providers & Services industry, placing it in the top 25.3%.
Is DaShenLin Pharmaceutical Group Co's 3-Year RORE % too high?
DaShenLin Pharmaceutical Group Co's current 3-Year RORE % is 27.55. The Healthcare Providers & Services industry median 3-Year RORE % is 1.57. DaShenLin Pharmaceutical Group Co's value of 27.55 is 1654.8% above this industry median. Based on the distribution chart, DaShenLin Pharmaceutical Group Co ranks #151 out of 597 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, DaShenLin Pharmaceutical Group Co has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does DaShenLin Pharmaceutical Group Co's 3-Year RORE % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, DaShenLin Pharmaceutical Group Co ranks #151 out of 597 companies for 3-Year RORE %. This puts DaShenLin Pharmaceutical Group Co in the upper half of its industry. The industry median 3-Year RORE % is 1.57. DaShenLin Pharmaceutical Group Co's value of 27.55 is 1654.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Healthcare Providers & Services company?
The median 3-Year RORE % among Healthcare Providers & Services companies is 1.57, based on 597 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DaShenLin Pharmaceutical Group Co's current 3-Year RORE % of 27.55 is 1654.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on DaShenLin Pharmaceutical Group Co and its competitors. For the Healthcare Providers & Services industry, the median 3-Year RORE % is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DaShenLin Pharmaceutical Group Co's current 3-Year RORE % is 27.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DaShenLin Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, DaShenLin Pharmaceutical Group Co (SHSE:603233) is currently considered Fairly Valued. The stock's GF Value™ is ¥18.78, compared to a current price of ¥18.24 — trading 2.9% below its estimated fair value. The current 3-Year RORE % is 27.55 and 1654.8% above the Healthcare Providers & Services industry median of 1.57. DaShenLin Pharmaceutical Group Co's overall GF Score™ is 96/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For DaShenLin Pharmaceutical Group Co (SHSE:603233), the current 3-Year RORE % is 27.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DaShenLin Pharmaceutical Group Co (SHSE:603233) Overvalued in 2026?
Based on GuruFocus' analysis, DaShenLin Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of ¥18.24 is trading 2.9% below its estimated GF Value™ of ¥18.78.
GuruFocus considers DaShenLin Pharmaceutical Group Co to be Fairly Valued.
Key valuation signals for SHSE:603233:
3-Year RORE %: 27.55
GF Value™: ¥18.78 vs. price of ¥18.24 (2.9% below fair value)
Industry Position: 1654.8% above the Healthcare Providers & Services median (#151 of 597)
No single metric tells the full story. See the SHSE:603233 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DaShenLin Pharmaceutical Group Co Ltd is engaged in the pharmaceutical manufacturing, retail, and wholesale business. The company is based on the development of the pharmacy chain. It primarily offers Chinese herbal medicine such as antibiotics and biochemical drugs. The business activities are geographically carried out through China.
96GF Score
Get the complete analysis for SHSE:603233
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603233 has been successfully added to your 
